News Summary

• Novo Nordisk ( NYSE:NVO | NVO Price Prediction ) laid out its long-term growth strategy at a capital markets day in London Monday morning.
• The plan didn’t calm investor worries about the company’s ability to defend the weight-loss market it helped build.
• Novo Nordisk stock is down 7% to $40.26, deepening a slide that has left the shares under water for the year.
• Eli Lilly stock is barely moving on the day, which matters because Lilly would be the natural place for a sector-wide obesity repricing to show up.